Specifically, RARγ has been shown to be deregulated in prostate cancer and to influence the androgen receptor cistrome in malignant cell lines (Long et al, 2019; Petrie et al, 2020; Bhowmick and Bhowmick, 2022; Yu et al, 2022; Wani et al, 2023). Here, AR is linked to prostate carcinoma.